Skip to main content
Open this photo in gallery:

South Korean Minister of Food and Drug Safety Oh Yu-Kyoung speaks during a briefing in Cheongju, South Korea, on June 29.Chun Kyung-hwan/The Associated Press

South Korea approved its first domestically developed COVID-19 vaccine, manufactured by SK bioscience Co Ltd, for general public use following positive clinical data, authorities said on Wednesday.

The SKYCovione vaccine was authorized for a two-dose regimen on people aged 18 or older, with shots given four weeks apart, according to the Ministry of Food and Drug Safety.

In a phase III clinical trial of 4,037 adults, SKYCovione induced neutralizing antibody responses against the SARS-CoV-2 parental strain, SK bioscience said in a statement.

It is not yet known how effective it is against Omicron and other COVID-19 variants.

The vaccine was jointly developed by the University of Washington’s Institute for Protein Design, with the support of global drugmaker GlaxoSmithKline (GSK).

SK bioscience said it would seek authorizations for distribution of SKYCovione in other countries and through global vaccine sharing facility COVAX, and for emergency use listing at the World Health Organization.

South Korean authorities have agreed a 200 billion won ($155-million) deal to buy 10 million doses of the vaccine, which can be stored under normal refrigeration conditions, and previously said they expected it to be rolled out from the second half of the year.

SK bioscience is now looking into its possible use for booster shots, and planning trials for adolescents and children, it added.

Nearly 87 per cent of South Korea’s 52 million population are fully vaccinated, with 65 per cent having also had a booster shot, according to the Korea Disease Control and Prevention Agency data.

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Follow related authors and topics

Authors and topics you follow will be added to your personal news feed in Following.

Interact with The Globe